$MAIA: An $80M Phase 3 oncology company with 17.8-month survival data, heavy insider buying, and partnerships with Regeneron, Roche and BeOne

{"summary": "Author pushes back on a bullish $MAIA post, arguing the cited deals are clinical supply agreements rather than partnerships and flagging high dilution.", "reason": "The author provides fundamental reasons (dilution pattern, nature of agreements) for the negative thesis.", "ideas": [{"symbol": "MAIA", "direction": "avoid", "thesis": "The author argues that MAIA's touted deals with Regeneron, Roche and BeOne are merely clinical supply agreements rather than true partnerships, undercutting the bull case. The company is pursuing a single product alone and has a high dilution pattern, which the author views as a negative. No specific catalyst or timeline was provided.", "thesis_short": "MAIA deals are supply agreements, high dilution", "quote": "These are clinical supply agreements lol not partnerships. \n\nSingle product, they’re going it alone and they have a high dilution pattern.", "confidence": 0.65, "sentiment": -0.6, "timeframe": "unspecified"}], "model": "gemini-3.1-flash-lite", "verified": true, "extraction_model": "deepseek-v4-flash"}